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A clear relationship between diabetes and cardiovascular disease has been established for decades. Despite this, the mechanisms by
which diabetes contributes to plaque formation remain in question. Some of this confusion derives from studies in type 2 diabetics
where multiple components of metabolic syndrome show proatherosclerotic eﬀects independent of underlying diabetes. However,
the hyperglycemia that deﬁnes the diabetic condition independently aﬀects atherogenesis in cell culture systems, animal models,
andhumanpatients.Endothelialcellbiologyplaysacentralroleinatheroscleroticplaqueformationregulatingvesselpermeability,
inﬂammation, and thrombosis. The current paper highlights the mechanisms by which hyperglycemia aﬀects endothelial cell
biology to promote plaque formation.
1.CardiovascularDiseaseand
DiabetesMellitus
Treatment of cardiovascular disease (CVD), manifesting in
the form of myocardial infarction, stroke, and peripheral
artery disease, represents one of biomedical sciences best
success stories over the past several decades [1, 2]. Through
clinical trials, epidemiology, and basic science, we have iden-
tiﬁeda hostofrisk factorsanddesigned drugstargeting these
risk factors that improve patient survival. The cholesterol-
lowering statin family of therapeutics reduces the 5-year risk
of cardiovascular-associated mortality by ∼25% in patients
with a history of prior CVD [3]. However, statins have not
shown similar protection in patients without a prior history
ofCVD[4,5],andCVDremainstheleadingcauseofdeathin
developed countries [2, 6]. Furthermore, the current obesity
epidemic threatens to worsen the incidence of CVD in the
coming years, undoing the progress we have made to this
point [7].
Morethan80%oftheCVD-associateddeathanddisabil-
ityisattributedtoatherosclerosis,theexcessiveaccumulation
of lipids, cholesterol, inﬂammatory cells, and connective tis-
sueinthevesselwall[8,9].Whileclinicallysilentfordecades,
atherosclerotic plaques can grow to occlude the vessel lumen
reducing blood ﬂow to target tissues [8, 9]. Although this
form of vessel occlusion can result in signiﬁcant discomfort
(e.g., angina pectoris), clinical events most often result from
thrombus formation due to plaque deterioration or rupture
resulting in a rapid cessation in blood ﬂow to target tissue.
Theories concerning the pathogenesis of atherosclerosis have
changed over the years, maturing concomitantly with our
understanding of vascular biology. We now know that ath-
erosclerosis is a chronic inﬂammatory disease with multiple
risk factors, such as hypercholesterolemia, dyslipidemia, dia-
betes, hypertension, and smoking, all playing roles in prop-
agating the local inﬂammatory response [9, 10].
Mouse models resulting in hypercholesterolemia, such as
the ApoE knockout mouse and the low density lipoprotein
(LDL) receptor knockout mouse, have allowed us to better
understand the pathogenesis of atherosclerotic plaque for-
mation and gain mechanistic insight into various biochemi-
cal pathways in mediating this response [11]. Atherosclerotic
plaque production in both mice and humans localizes to
discrete regions of the vascular tree that experience alter-
ationsinbloodﬂow,suchasvesselcurvatures,branchpoints,
and bifurcations [12]. Coupled with endothelial cell culture2 International Journal of Vascular Medicine
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Figure 1: Stages ofatherosclerotic plaque formation. Early apoB-containinglipoprotein accumulation andmonocytebindingdrivetheearly
stages of plaque development forming fatty streaks in the vessel wall. While these processes continue in advanced atherosclerosis, monocyte
cell death, smooth muscle recruitment, and matrix deposition are hallmarks of atheroma formation. Superﬁcial plaque erosion and rupture
of the smooth muscle-rich ﬁbrotic cap cause plaque-associated thrombosis culminating in a clinical event.
models, we now understand that shear stress, the frictional
forcegeneratedbyﬂowingblood,exertsaprotectiveeﬀecton
thevascularendotheliumtolimitinﬂammation,thrombosis,
andendothelial turnover[12,13].Incontrast,turbulentﬂow
promotes endothelial permeability and proinﬂammatory re-
sponses. Increased endothelial permeability and altered inti-
mal matrix protein composition promote deposition of
apoB-containing LDL particles within the intimal matrix
(Figure 1)[ 14, 15]. Oxidation of LDL within the vessel wall
enhances its proinﬂammatory properties resulting in local
endothelial cell expression of inﬂammatory proteins (e.g.,
intercellular adhesion molecule (ICAM-1), vascular cell
adhesion molecule (VCAM-1)) [8, 16]. Monocytes target
to these regions of local inﬂammation and engulf the
lipid deposits forming foam cells (Figure 1). These early
plaque precursors, visible histologically as fatty streaks,
accumulate smooth muscle cells, necrotic foam cell debris,
lipids, and ECM proteins as they transition to advanced
atherosclerotic plaques [8, 9]. While current methods to
detectatherosclerosisrelyonplaquestenosis,morethan60%
of myocardial infarctions are caused by plaques showing
less than 50% stenosis [17]. Consistent with this, plaque
growth alone rarely results in vessel blockage as blood
vessels adapt by expanding to maintain lumen size and
aﬀe c t e dt i s s u e sp r o m o t en e wb l o o dv e s s e lg r o w t h( t e r m e d
angiogenesis) to restore blood supply [8]. Rather, cardio-
vascular events most often result from thrombus forma-
tion and acute vessel occlusion following plaque rupture
or superﬁcial plaque erosion (Figure 1)[ 18]. Plaque rup-
ture is hindered by the plaque’s ﬁbrotic cap, a smooth
muscle cell and extracellular matrix-rich region overlying
the thrombotic necrotic core. Local smooth muscle cell
apoptosis and enhanced matrix proteolysis by leukocyte-
derived proteases weaken the cap enhancing the likelihood
of plaque rupture; this is termed the “vulnerable plaque”
[18, 19]. While plaque rupture accounts for approximately
70% of all thrombotic CVD events, the remaining 30%
occurs following superﬁcial plaque erosion resulting in
the loss of the protective endothelial cell layer and expo-
sure of the highly thrombogenic intimal matrix (Figure 1)
[18, 19].
1.1.DiabetesMellitusandCVD. TheancientGreekphysician
AretaeusofCappadociausedthetermdiabetestorefertodis-
easesassociatedwiththeexcessproductionofurine[20].The
English physician Thomas Willis coined the term diabetes
mellitus, literally translated “honey-sweet diabetes,” in 1645
in reference to the sweet-tasting urine of one of his patients
[20]. Today, the term diabetes mellitus refers to the family
of metabolic conditions associated with the loss of normal
glucose regulation resulting in hyperglycemia. In 2000, there
were171milliondiabeticsworldwidecomprising2.8%ofthe
population; this number is projected to reach 366 million
(4.4% of the population) by 2030 [21]. Type 1 diabetes,
also known as insulin-dependent diabetes mellitus (IDDM),
typically results from autoimmune destruction of pancreatic
islet cells responsible for insulin secretion within the ﬁrst few
decades of life. In contrast, type 2 diabetes, or non-insulin-
dependent diabetes mellitus (NIDDM), involves progressive
insulin resistance as target tissues become insensitive to
insulin resulting in chronic hyperglycemia and hyperinsu-
linemia. Chronic hyperglycemia in patients is measured by
determiningthelevelofglycatedhemoglobin(HbA1c).Since
red blood cells have a 3-month life-span, HbA1c values pro-
vide an estimation of average blood glucose levels over time
[22]. In healthy patients, HbA1c levels range from 4.0
to 5.9% corresponding to a blood glucose level of 68 to
123mg/dL. An HbA1c level greater than 6.5% (140mg/dLInternational Journal of Vascular Medicine 3
blood glucose) is used as a criterion for the diagnosis of
diabetes. However, the HbA1c level does not provide any
information concerning periodic spikes in hyperglycemia
which may be just as harmful as a sustained higher average
glucose. As such, continuous blood glucose monitoring sys-
tems are becoming more and more common.
Diabetics have a 2- to 4-fold higher risk for cardiovascu-
lar events [23], and nearly 80% of diabetes-associated deaths
are caused by CVD [24] .A ss u c h ,d i a b e t e si sr e g a r d e da sa
coronary heart disease risk equivalent, meaning that the risk
for CVD is the same as an individual with a previous CVD
event [25]. The enhanced CVD risk in diabetic patients is
larger for women than men because women generally en-
joy a protection from CVD during their reproductive years,
a n dt h i sp r o t e c t i o ni sl o s ti nd i a b e t i c s[ 26]. Type 1 and type
2 diabetic patients show a similar atherosclerotic plaque
proﬁle with an increase in necrotic core size and a de-
crease in the ﬁbrotic cap size [27, 28]. However, type 2 dia-
betics show enhanced atherosclerotic plaque burden with
more distal plaques compared to type 1 diabetics [28].
Consistent with this disparity, type 2 diabetes represents a
multifactorialproatherogeniceﬀectinvolvingvariousaspects
ofmetabolicsyndrome,acombinationofhyperglycemia,hy-
perlipidemia, obesity, and hypertension [29]. Obesity, par-
ticularly abdominal obesity, results in enhanced expres-
sion of systemic circulating proinﬂammatory cytokines ex-
pression and reduced levels of protective factors such as
adiponectin [30, 31]. Furthermore, obesity is linked with
the hyperlipidemia and hypercholesterolemia classically as-
sociated with atherosclerotic plaque formation [30, 31]. Due
to the presence of these confounding factors, the speciﬁc
role of hyperglycemia on atherosclerotic plaque formation
in type 2 diabetics has been diﬃcult to discern.
Despite these complications, considerable data exist link-
inghyperglycemiaalonetoacceleratedatherosclerosisintype
1 diabetics, where these confounding atherogenic factors are
often absent. Children with type 1 diabetes show enhanced
carotid intimal-medial thickness (IMT) compared to nondi-
abetics [32]. Postmortem studies of young patients and
children with type 1 diabetes show enhanced fatty streak
formation in the absence of dyslipidemia suggesting that
hyperglycemia is an independent risk factor for early plaque
development [33, 34]. Animal models of type 1 diabetes
include pancreatic β-cells destruction by the DNA-alkylating
mechanism of streptozotocin [35], targeted autoimmune
destruction of β-cells due to transgenic expression of viral
proteins (RIP-GP mice) [36], and decreased proinsulin
production and processing due to mutations in the insulin
2 gene (Ins2Akita (Mody)m o u s e )[ 37]. Diabetes alone in
these animals does not appear to be suﬃcient for signiﬁcant
atherosclerotic progression. However, when coupled with
genetic modiﬁcations to the LDL-R or ApoE genes to in-
duce a more human lipoprotein proﬁle, diabetic mice show
enhanced atherosclerotic plaque production compared to
their nondiabetic littermates [38–40]. Hyperglycemia is
strongly associated with early fatty streak formation in
atherosclerosis-prone mice, while progression to advanced
atherosclerotic plaques requires dyslipidemia [41]. However,
diabetes in these models is often associated with elevated
hypercholesterolemia compared to nondiabetic controls,
making it diﬃcult to elucidate whether the observed eﬀects
on atherogenesis are due to hyperglycemia speciﬁcally.
Clinical trials have both corroborated and complicated
the role of hyperglycemia in atherosclerosis. The DECODE
trial showed an association between hyperglycemia and im-
paired glucose tolerance and CVD [42, 43]. However, studies
toelucidate whethertight glycemiacontrolreducesCVD risk
have produced mixed results, likely attributed to the timing
of the treatment and the inclusion of low CVD risk or high
CVD risk patients. The Diabetes Control and Complications
Trial(DCCT)examinedtheeﬀectoftightglycemiccontrolin
young type 1 diabetics with low CVD risk. Within the initial
time period of the study, the authors demonstrated reduced
microvascular complications but only demonstrated an
insigniﬁcant (41%) reduction in CVD events [44]. However,
theeventrateforCVDinthispopulationwasverylow.Inthe
Epidemiology of Diabetes Interventions and Complications
(EDIC) study, a 10-year followup of the DCCT trial, the
investigators found a signiﬁcant 42% reduction in CVD
events [45]. The UK Prospective Diabetes Study (UKPDS)
examined the role of tight glycemic control in newly
diagnosed type 2 diabetics. Similarly, this group found a
nonsigniﬁcant reduction in CVD events (16%) during the
course of the trial [46] but a signiﬁcant reduction in CVD
events in a 10-year follow-up study [47]. However, clinical
trials examining stringent glycemic control in patients with
an already high CVD risk (Action to Control Cardiovascular
RiskinDiabetes(ACCORD),ActionindiabetesandVascular
disease: Preterax and Diamicron MR controlled evalua-
tion (ADVANCE), Veterans Aﬀairs Diabetes Trial (VADT))
showed no beneﬁcial eﬀect on CVD [48, 49]. Furthermore,
the ACCORD trial demonstrated an increase in CVD-asso-
ciated death in the intensively controlledgroup (HbA1c< 6);
this eﬀect has been attributed to enhanced weight gain, in-
creased insulin injections, and increased incidence of hypo-
glycemia. These diﬀerential responses may result from the
timing of glycemic control, as patients in the VADT trial
that were within the ﬁrst 12 years of diagnosis showed a
beneﬁt in the intensive treatment arm [50]. Taken together,
data from clinical trials suggest that glucose control early fol-
lowing the diagnosis of diabetes confers protection that is
often not evident for decades despite the cessation of dif-
ferential treatment; consistent with the hypothesis that hy-
perglycemia plays a larger role in plaque initiation than
plaque progression.
2.EndothelialCellActivationand
Dysfunction in Atherosclerosis
The endothelial cell layer regulates multiple aspects of vas-
cular physiology such as maintaining a semipermeable
blood-tissue barrier, coordinating leukocyte traﬃcking, pre-
venting thrombosis, and altering vascular tone [51]. During
inﬂammatory responses, endothelial cells undergo a phe-
notypic conversion, termed endothelial cell activation, char-
acterizedbyenhancedpermeability,elevatedleukocyteadhe-
sion molecule expression, and reduced antithrombotic prop-
erties [52]. Mediators of endothelial cell activation are4 International Journal of Vascular Medicine
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Figure 2: Interplay between endothelial cell dysfunction and endothelial cell activation. (a) Cytokines and oxidized LDL stimulate
endothelial cell permeability and NF-κB-dependent inﬂammatory gene expression. ROS appear to play a central role mediating both
responses.(b)Inadditiontoitsvasodilatoryproperties,NOpromotesbarrierstability,limitsinﬂammation,inhibitsplateletaggregation,and
limits SMC proliferation. Loss of these protective properties in endothelial cell dysfunction therefore perpetuates endothelial cell activation.
diverse and include proinﬂammatory cytokines (tumor
necrosis factor α (TNFα), interleukin-1β (IL-1β)), bacte-
rial (lipopolysaccharide) and endogenous toxins (oxLDL),
vasoconstrictors (angiotensin II, endothelin-1), mechani-
cal forces (shear stress, stretch), and extracellular matrix
proteins (ﬁbronectin, ﬁbrinogen) [13, 52–54]. The early
rapid phase of endothelial cell activation, termed type 1
activation, involves the remodeling of endothelial cell-cell
junctions enhancing monolayer permeability (Figure 2(a))
and the export of Weibel-Palade bodies presenting P-Selectin
and vWF at the endothelial cell surface [52]. Activation
of proinﬂammatory transcription factors such as nuclear
factor κB( N F - κB) drives the latter phase, termed type 2 ac-
tivation, invoking the transcription and expression of proin-
ﬂammatory genes such as E-selectin, ICAM-1, VCAM-1,
chemokines (interleukin-8 (IL-8), monocyte chemotactic
protein-1 (MCP-1)), and cytokines (IL-1β,T N F α)[ 52]
(Figure 2(a)). The selectin family of cell adhesion molecules
inducescaptureandtetheringofleukocytesinthecirculation
resultinginleukocyterollingacrosstheendothelium.Rolling
provides suﬃcient reduction in velocity for leukocyte ﬁrm
adhesion to ICAM-1 and VCAM-1 on the endothelial sur-
faceandsubsequenttransendothelialmigration[55].Presen-
tation of chemokines on the endothelial cell surface activates
the leukocyte integrins VLA-4, LFA-1, and Mac-1 increas-
ing their aﬃnity for their ICAM-1/VCAM-1 ligands [55].
Transgenic mice lacking MCP-1, ICAM-1, or the fourth Ig
domain of VCAM-1 (VCAM-1 expression is necessary for
chorioallantoic fusion, rendering VCAM-1 knockouts lethal)
severely limits atherosclerosis [56–60]. These data suggest
that atherosclerotic plaque development requires endothelial
cell activation involving enhanced expression of proinﬂam-
matory adhesion molecules and chemokines.
Endothelial cell dysfunction is deﬁned by a decrease in
the bioavailability of nitric oxide (NO), a critical regulator of
vascular tone [61]. Multiple stimuli, including shear stress
[62], acetylcholine [63], bradykinin [64], insulin [65, 66],
and adiponectin [67], activate endothelial cell NO synthase
(eNOS) to convert L-arginine into NO and citrulline. Endo-
thelialcelldysfunctiontypicallyoccurswhentheseprotective
stimuli are diminished, such as at sites of turbulent blood
ﬂow (decreased shear stress), in diabetes (decreased insulin
signaling),andinobesity(decreasedadiponectin).Decreases
in eNOS activity and expression, increases in eNOS uncou-
pling, and direct NO scavenging all mediate endothelial cell
dysfunction [61]. eNOS uncoupling appears to be particu-
larlydeleteriousduetosimultaneousdecreaseinNOproduc-
tion and increased production of the free radical superoxide.
Multiple mechanisms have been proposed to mediate eNOS
uncoupling, such as diminished bioavailability of L-arginine
[68],accumulationoftheendogenouseNOSinhibitor asym-
metric dimethyl L-arginine (ADMA) [69], oxidation of the
critical eNOS cofactor tetrahydrobiopterin [68, 70], and di-
rect S-glutathionylation of critical cysteine residues in eNOS
[71]. These modiﬁcations disrupt electron ﬂow in eNOS
causing incomplete catalysis of L-arginine and superoxide
production [72, 73]. Superoxide can react with remaining
intracellular NO further reducing cellular NO levels and
resulting in the formation of peroxynitrite, a potent oxidant.
Endothelial cell dysfunction is regarded as an early
step in atherosclerotic plaque formation primarily due
to its eﬀect on endothelial cell activation. Endothelial-
derived NO reduces integrin activation on platelets [74, 75]
and leukocytes [76] preventing thrombosis and leukocyte
adhesion (Figure 2(b)). NO signaling in the endothelium
promotes endothelial barrier integrity [77]a n dr e d u c e s
both Weibel-Palade body exocytosis (type 1 activation)
[78]a n dN F - κB-dependent proinﬂammatory gene expres-
sion (type 2 activation) [79, 80]( Figure 2(b)). Turbu-
lent ﬂow, cytokines, and oxLDL reduce eNOS expres-
sion and shorten the half-life of eNOS mRNA perpetu-
ating endothelial cell dysfunction and promoting inﬂam-
mation (Figure 2(b))[ 81]. Transgenic mice deﬁcient in
eNOS exhibit multiple vascular defects, such as hyper-
tension, enhanced leukocyte rolling and ﬁrm adhesion,
and vascular remodeling [82, 83]. Conversely, transgenicInternational Journal of Vascular Medicine 5
eNOS overexpression paradoxically enhanced atherosclerotic
plaque formation due to eNOS uncoupling and superoxide
production; supplementation with critical eNOS cofactor
tetrahydrobiopterinreducedthisuncouplinganddiminished
plaque formation in these mice [84]. Subsequent studies
with tetrahydrobiopterin supplementation in ApoE mice
demonstrated reduced plaque progression suggesting that
eNOS uncoupling may be involved in atherosclerotic plaque
progression in the absence of eNOS overexpression as well
[85, 86]. Taken together, these data suggest a critical role
for endothelial cell dysfunction in the propagation of both
endothelial cell activation and atherosclerotic plaque forma-
tion.
3.HyperglycemiainEndothelialCell
DysfunctionandActivation
The eﬀect of hyperglycemia on endothelial cells closely mim-
ics that of inﬂammatory initiators. Endothelial cells exposed
to hyperglycemic cell culture media show reduced NO pro-
duction [87, 88] with enhanced NF-κBa c t i v a t i o n[ 89–91],
inﬂammatory gene expression [92–95], and leukocyte re-
cruitment [93, 94, 96]. Transient hyperglycemia causes epi-
genetic modiﬁcations in the promoter of the NF-κBp 6 5
subunit inducing a sustained increase in NF-κB expression
andNF-κB-dependentVCAM-1andMCP-1expressionfor6
days after restoration of normoglycemia [97], a phenomena
termed epigenetic memory. Animal models and studies on
human patients have similarly demonstrated an association
between hyperglycemia and endothelial cell dysfunction and
activation. However, it should be noted that most cell culture
systems and animal models tend to utilize glucose levels
(20–25mM; 360 to 450mg/dL) above that seen in diabetic
humans (typically 7.8 to 10mM; 140–180mg/dL) to acceler-
ate the occurrence of diabetic complications, and care must
be taken when extrapolating results from these experimental
systems to the human disease. In the subsequent sections, we
will describe the roles of reactive oxygen species, advanced
glycation end products (AGEs), metabolic pathway ﬂux, and
protein kinase C signaling in mediating the eﬀects of hy-
perglycemia-induced endothelial cell dysfunction and acti-
vation.
3.1. Reactive Oxygen Species (ROS). Multiple atherogenic
stimuli promote endothelial cell dysfunction and activation
through enhanced production of ROS. Several ROS play im-
portant roles in endothelial pathophysiology including the
free radicals superoxide (O
•−
2 ) and the hydroxyl radical
(OH•) as well as the non-free radical species hydrogen per-
oxide (H2O2), peroxynitrite (ONOO-/ONOOH), and hy-
pochlorous acid (HClO) [98]. Turbulent ﬂow [99, 100],
atherogenic cytokines (TNFα,I L - 1 β)[ 101, 102], vasocon-
strictors (angiotensin II) [103] and oxidized LDL [104]a l l
induce ROS-dependent NF-κB activation to drive endothe-
lial cell expression of proinﬂammatory and prothrombot-
ic genes [105, 106]. In addition to inﬂammatory gene ex-
pression, ROS reduce endothelial barrier function [107, 108]
contributing to lipoprotein deposition and subsequent
oxidative modiﬁcation of LDL particles in the vessel wall
[98, 109]. Furthermore, ROS stimulates endothelial cell
dysfunction by scavenging NO directly or by oxidative modi-
ﬁcationoftetrahydrobiopterinresultingineNOSuncoupling
[110]. Thus, ROS reduce endothelial cell NO production
(scavenging, eNOS uncoupling) while activating both direct
(NF-κB activation) and indirect mediators (LDL oxidation)
of endothelial cell activation.
Hyperglycemia stimulates cellular ROS production by
four major sources including direct glucose autooxidation
[111], mitochondrial superoxide production [112], eNOS
uncoupling [113], and AGE-dependent NADPH oxidase
activation (Figure 3(a)) [72, 73]. Glucose autooxidation and
mitochondrialsuperoxidearelikelytobetheinitialcontribu-
tors to ROS-mediated dysfunction elicited by hyperglycemia
[72]. Trace amounts of free metals catalyze glucose auto-
oxidation resulting in systemic oxidant stress [114]. Glucose
oxidation during glycolysis produces ROS that are generally
held in check by the cell’s antioxidant defenses, including
superoxide dismutase (SOD), thioredoxin, glutathione per-
oxidase (GP), and catalase [115]. However, these systems be-
come overloaded during hyperglycemia. Whereas many cells
downregulate glucose transporters (GLUTs) in response to
hyperglycemia, endothelial cells retain expression of non-
insulin-dependent GLUTs allowing intracellular glucose to
rise concomitantly with extracellular glucose concentrations
(Figure 3(a)) [116]. Enhanced glycolytic oxidation and the
disruption of the mitochondrial electron transport chain
promoting electron shuttling into molecular oxygen stimu-
lates oxidant stress. eNOS uncoupling in response to ROS
production further perpetuates oxidant stress under hyper-
glycemic conditions (Figure 3(b)) [117]. During chronic
hyperglycemia, AGE production contributes to ROS pro-
duction through receptor-mediated NADPH oxidase acti-
vation (Figure 3(b)). It should be noted however, that
ROS production through distinct cellular sources (NADPH
oxidase, mitochondria) can lead to ROS production at sec-
ondary sites [72, 118], and the relative contributions of each
source are likely to ﬂuctuate with disease state and control
(hyperglycemic spikes versus AGEs).
Multiple studies have found that preventing ROS pro-
duction or enhancing the cell’s antioxidant systems limits
the capacity of hyperglycemia to promote endothelial dys-
function and activation. Inhibiting mitochondrial superox-
ide production prevents hyperglycemia-induced ROS pro-
duction, AGE accumulation, and PKC activation suggest-
ing this pathway plays a central role in hyperglycemia-
induced endothelial cell responses [119]. Addition of the
antioxidant N-acetyl-L-cysteine prevented hyperglycemia-
associated endothelial cell apoptosis [120], whereas the anti-
oxidant coenzyme Q10 inhibits high-glucose-induced proin-
ﬂammatory gene expression and monocyte binding [121].
Reducing hyperglycemia-induced ROS production using a
mitochondrial complex II inhibitor (thenoyltriﬂuoroacetone
(TTFA)) or a Mn SOD mimetic (Mn(III)tetrakis(4-benzoic
acid) porphyrin chloride (MnTBAP)) abrogates inﬂamma-
tory gene expression [122, 123] and enhances NO produc-
tion [123]. Taken together, these studies suggest that limiting
ROS production reduces hyperglycemia-induced endothelial
cell dysfunction and activation.6 International Journal of Vascular Medicine
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Consistent with cell culture models, mouse models of
type 1 diabetes show enhanced endothelial oxidative stress,
inﬂammatory gene expression, and leukocyte recruitment
[124–126]. Pharmacological and genetic modiﬁcations of
antioxidant pathways support a role for oxidative stress in
hyperglycemia-associated endothelial cell dysfunction and
activation. Rings of rabbit aorta treated for 6 hours in
hyperglycemic media show reduced ACh-mediated vaso-
dilation compared to normoglycemic controls, and multiple
antioxidants (superoxide dismutase, catalase, deferoxamine,
or allopurinol) were suﬃcient to reverse hyperglycemia-
associated impairment in vasodilation [127]. Similarly, mul-
tiple antioxidants restored vasodilation in aortic rings
isolated from diabetic rats [128, 129]. Diabetic ApoE/glu-
tathioneperoxidase-1doubleKOmiceshowenhancedather-
osclerosis compared to diabetic mice deﬁcient in ApoE
alone associated with enhanced VCAM-1 expression and
macrophage recruitment [130]. Conversely, the GP-1 mim-
etic ebselen reduces endothelial dysfunction, proinﬂamma-
tory gene expression, and atherosclerotic plaque formation
in diabetic mice [131, 132]. Antioxidant treatments also
reduce endothelial permeability resulting from hypergly-
cemia [133, 134]. Taken together, these data provide strong
evidence that antioxidants protect endothelial cells from
hyperglycemia-induced endothelial cell dysfunction and
activation.
Although many antioxidant therapies targeting multiple
sources of ROS in experimental models have shown promise,
several clinical trials utilizing antioxidants appear to confer
no signiﬁcant protection [73, 135]. In the Heart Outcomes
Prevention Evaluation (HOPE) trial, 3654 diabetic patients
receiving supplementation with vitamin E or placebo for
4.5 years failed to show any cardiovascular beneﬁt for vit-
amin E [136]. Similarly, the Secondary Prevention with
Antioxidants of Cardiovascular Disease in End Stage Renal
D i s e a s e( S P A C E )t r i a l[ 137], Study to Evaluate Carotid
Ultrasound Changes in Patients Treated with Ramipril and
VitaminE(SECURE)trial[138],andthePrimaryPrevention
Project (PPP) trial [139] all failed to show beneﬁcial eﬀects
of antioxidants in diabetes-associated cardiovascular disease.
However, the lack of a clinical beneﬁt in these trials does not
disprove the role of ROS in CVD as there are several reasons
why these studies may have failed including uncertain dose
requirements for vitamin E, short time frame of clinical
trials, and the use of high risk patients with advanced CVD
[140].International Journal of Vascular Medicine 7
3.2. AGE/RAGE. Another major mechanism of diabetes-
associated endothelial cell dysfunction and activation in-
volves hyperglycemia-associated formation of AGEs. Glyca-
tion involves the nonenzymatic addition of a carbohydrate
moiety onto proteins; this should not be confused with
glycosylation that takes place in the ER and Golgi resulting
in protein maturation. The nonreversible formation of AGEs
results from several reversible reactions, collectively termed
the Maillard reaction. First, a reducing sugar, such as glu-
cose or fructose, attaches to the α-amino group of either
the amino terminus of proteins or lysine residues via nucle-
ophilic attack: the product is known as a Schiﬀ base [141].
This can undergo an Amadori rearrangement forming keto-
amines. From here, these ketoamines, synonymously ter-
med Amadori products, take one of two pathways: an
oxidative or nonoxidative pathway forming irreversible AGE
modiﬁcations [142, 143]. Hyperglycemia causes excessive
glycation of proteins found in serum (e.g., albumin, hemo-
globin, and LDL) and in the vessel wall (e.g., collagen, ﬁ-
bronectin). However, AGE formation by intracellular glyco-
lysis-derived dicarbonyl precursors (glyoxal, methylglyoxal,
and 3-deoxyglucosone) occurs at a rate several orders of
magnitude higher than nonenzymatic glycation, suggest-
ing that these intermediates may be primarily responsible
for both intracellular and extracellular AGE production
(Figure 3(b)) [144, 145]. Glyoxal arises from glucose au-
tooxidation, whereas methylglyoxal formation occurs in
response to glyceraldehyde-3-phosphate and dihydroxy-
acetone phosphate fragmentation [146–148]. While en-
hanced during hyperglycemia, AGE formation is a naturally
occurring process with endogenous negative regulators (ex.
glyoxalase I) that degrade the AGE-inducing dicarbonyl in-
termediates [146]. Interestingly, AGE accumulation during
normal aging occurs concomitant with a decrease in glyox-
alase I expression [149], and glyoxalase I expression is associ-
ated with enhanced lifespan of Caenorhabditis elegans [150].
AGEs carry a large arsenal of weaponry with which to
exacerbate diseases, including both receptor-mediated and
receptor-independent eﬀects. AGEs bind to multiple cell
surface receptors including the “receptor for AGE” (RAGE)
[151], AGE receptor 1 (AGER1), AGER3, and CD36 [152].
A member of the immunoglobulin superfamily, RAGE re-
gulates AGE-associated endothelial cell dysfunction and ac-
tivation. While RAGE receptor signaling is not well under-
stood, RAGE ligation stimulates endothelial ROS production
[153], and the NADPH oxidase inhibitor diphenyliodonium
(DPI) signiﬁcantly blunts this induction (Figure 3(b)) [154].
AGE-dependent proinﬂammatory gene expression (VCAM-
1, E-selectin) in endothelial cells similarly requires the RAGE
receptor [155] and NADPH oxidase activation [154, 156]. In
addition to ROS-mediated NO scavenging, AGEs decrease
eNOS expression and L-citrulline production (readout of
NO production) in endothelial cells [157], and AGEs inhibit
histamine-induced NO production in endothelial cells
associated with reductions in eNOS serine phosphorylation
[158]. Consistent with this, Gao and collaborators show that
the impaired vasodilation in blood vessels of diabetic mice is
endothelium dependent and RAGE sensitive [159].
In contrast to the proinﬂammatory RAGE receptor, the
alternative AGE receptors AGER1, AGER3, and CD36 stimu-
late AGE degradation [152], with AGER1 suppressing AGE-
induced ROS production [160]. This disparity suggests that
AGE-associated inﬂammation can be regulated at the level
of receptor expression. Activation of NO-associated PKG
signaling in endothelial cells by treatment with the PDE5
inhibitor Vardenaﬁl reduces RAGE gene expression, suggest-
ing that healthy levels of NO/PKG signaling suppress the
AGE/RAGE insult [161].Incontrast,hyperglycemia-induced
ROS production promote RAGE expression [162], suggest-
ing a synergistic eﬀect between hyperglycemia-associated
glycolytic oxidant stress and AGE/RAGE-dependent oxidant
stress.
Receptor-independent eﬀects of AGEs include extracel-
lular matrix modiﬁcation [163], NO scavenging [164], and
glycation of both signaling proteins [165]a n dL D L[ 166].
Since AGE formation is irreversible and turnover of ECM
is slow, hyperglycemia stimulates considerable glycation of
extracellular matrix proteins resulting in vessel stiﬀening
through crosslinking type I collagen and elastin [167–169].
Vessel stiﬀening contributes to systemic hypertension and
increases the strain on the vessel wall [170]. AGE-dependent
NO scavenging perpetuates stiﬀening by enhancing smooth
muscle proliferation and increased contractility [164, 171].
Endothelial cell interactions with subendothelial basement
membrane proteins initiate signaling pathways that reduced
endothelialcellactivation[100,172].Glycationofthesuben-
dothelial matrix proteins laminin and collagen IV disrupts
matrix self-assembly and prevents endothelial cell adhesion
and spreading [169, 173, 174]. Therefore, disrupted interac-
tion with the basement membrane may limit its protective
properties while enhancing endothelial cell loss (superﬁcial
plaque erosion). In addition to matrix modiﬁcations, gly-
cation of intracellular signaling proteins by methylglyoxal
activates the endothelial cell stress response (JNK, p38)
[175]. However, methylglyoxal inhibits NF-κBa c t i v a t i o nb y
modiﬁcation of Cys38 blocking DNA binding [165], and
JNK signaling in the absence of NF-κBc a np r o m o t ea p o p -
tosis [176]. Consistent with this, methylglyoxal stimulates
endothelialcellapoptosisalthoughthesignalingmechanisms
employed have not been addressed directly [177]. Lastly,
glycation of LDL may be as deleterious as LDL oxidation
in promoting endothelial cell activation [178]. Glycated LDL
binds to the RAGE receptor stimulating endothelial cell dys-
function through calpain-dependent eNOS degradation and
promoting inﬂammatory gene expression through NADPH
oxidase-dependent ROS production [179–182].
Several lines of evidence suggest that AGE formation
mediates hyperglycemia-associated cardiovascular disease.
Pharmacological inhibitors of AGE formation (alagebrium
chloride (ALT-711), pyridoxamine dihydrochloride) signif-
icantly reduce atherosclerotic plaque formation in diabetic
ApoE null mice [183, 184]. Early clinical trials using ALT-
711 demonstrated enhanced arterial compliance [185]a n d
improved ﬂow-mediated vasodilation [186]i na g e dh y p e r -
tensive patients. Despite these early successes, Alteon (the
producer of ALT-711) encountered ﬁnancial hardship and8 International Journal of Vascular Medicine
halted drug development. Overexpression of methylglyoxal-
degrading enzyme glyoxalase I reduces AGE production
and oxidant stress in diabetic rats [187]. Furthermore,
polymorphisms in glyoxalase I are associated with carotid
atherosclerosis in type 2 diabetics [188, 189]. A soluble splice
variant of RAGE lacking the cytosolic and transmembrane
domain scavenges circulating AGEs counteracting their
proinﬂammatory eﬀects. Therapeutic intervention utiliz-
ing exogenous sRAGE treatment dose-dependently inhibits
leukocyte inﬁltration, plaque formation, and progression of
existing plaques in mouse models [190, 191]. One caveat
to these studies is the interaction of RAGE with oxLDL,
suggesting sRAGE may reduce atherosclerosis by scavenging
oxLDL. However, ApoE/RAGE double knockout mice and
ApoE mice expressing endothelial-speciﬁc dominant nega-
tive RAGE show reductions in both endothelial cell dysfunc-
tion and atherosclerotic plaque formation [192], suggesting
that RAGE plays an important role in atherosclerotic plaque
formation. RAGE antagonists (TTP488) and humanized
sRAGE are making their way through early clinical trials
for diabetic nephropathy, Alzheimer’s disease, and acute
lung injury; however no trials for cardiovascular disease are
currently underway [193].
3.3. Metabolic Pathway Flux. In addition to uncoupling the
electron transport chain, hyperglycemia pushes glucose ﬂux
through alternative metabolic pathways, including the polyol
and hexosamine pathways (Figure 3(a)). The polyol pathway
consists of aldose reductase and sorbitol dehydrogenase,
which mediate the conversion of glucose to sorbitol via
NADPH oxidation, and sorbitol to fructose via NAD+ reduc-
tion,respectively.Inhyperglycemicconditions,itissuggested
that up to 30% of metabolized glucose ﬂuxes through the
polyolpathway[194]versusthe ∼3%undernormo-glycemic
conditions [195]. Hyperglycemia stimulates aldose reductase
expression and may aﬀect activation through ROS-de-
pendent S-thiolation, S-nitrosation, and glutathiolation of
a critical cysteine residue (Cys298) [196, 197]. Early studies
demonstrated that limiting aldose reductase activity in the
lens inhibits cataract formation driven by sorbitol accumu-
lation [196, 198–200]; thus aldose reductase was postulated
to mediate peripheral hyperglycemic complications. This
eﬀect was proposed to be due to osmotic pressure caused
by sorbitol accumulation. However, multiple antioxidants
were later found to limit cataract formation under hyper-
glycemic conditions without aﬀecting sorbitol accumulation
suggesting a more complex role for aldose reductase in
hyperglycemia-associated diabetic complications [196, 201–
203].
Aldose reductase is expressed in multiple tissue beds and
performs highly context-dependent functions [204]. Inhibit-
ing aldose reductase limits NF-κB activation and proin-
ﬂammatory gene expression in response to hyperglycemia
and proinﬂammatory cytokines, suggesting aldose reduc-
tase plays a proinﬂammatory function in endothelial cells
[205, 206]. The proinﬂammatory eﬀect of polyol pathway
ﬂux could be explained by the reduction of NADPH
and NAD+ availability, resulting in reduced production
of NO, diminished levels of reduced glutathione, and
unbalanced redox stress [72]. However, aldose reduc-
tase also catalyzes the reduction of aldehydes produced
by lipid peroxidation and glutathiolation [196, 207–209].
Since these aldehydes possess proinﬂammatory proper-
ties, aldose reductase may also function as an anti-
inﬂammatory/detoxiﬁcation mediator [209]. Mouse models
of atherogenesis underscore the complexities of aldose
reductase activity in the disease setting. Whereas aldose
reductase deletion (global) enhances atherosclerotic plaque
in the hypercholesterolemic ApoE-null mouse on high-
fat diet as well as in streptozotocin-induced diabetes [210],
general and endothelial targeted overexpression of human
ARinmodelsofhypercholesterolemiaalsoshowedenhanced
plaque size in diabetic animals [211, 212]. This discrepancy
may be due to the signiﬁcantly reduced levels of aldose
reductase in mice, which could limit polyol pathway ﬂux and
diminish its potential proinﬂammatory role [197].
In contrast to the extensive research on the polyol path-
way in hyperglycemia, the hexosamine pathway has received
considerably less attention, possibly owing to the lack of
speciﬁc inhibitors [213, 214]. In the physiological setting,
fructose-6-phosphate proceeds from the glycolytic path-
way to produce glucosamine-6-phosphate via enzymatic
activity of glutamine:fructose-6-phosphate amidotransferase
(GFAT). Several intermediate reactions lead to synthesis
of UDP-N-acetylglucosamine (GlcNAc), a nucleotide donor
utilized in the ER and golgi for glycosylation of various
glycoproteins, lipids, and proteoglycans. Additionally, UDP-
GlcNAc is a substrate of O-GlcNAc transferase (OGT), lead-
ing to production of O-linked GlcNAcylated Ser and Thr
residues in a wide variety of intracellular proteins [215, 216].
TheregulationofmanyprocessesbyO-GlcNAcmodiﬁcation
has led to the comparison of O-GlcNAcylation to phosphor-
ylation events and redox modiﬁcation of proteins as a re-
gulator of protein activity, with emphasis on the limited
expression of enzymes involved in the regulation of O-
GlcNAcylation versus the plethora of cellular kinases medi-
ating phosphorylation events [217].
Protective roles of O-GlcNAcylation have been reported
in cardiac ischemia/reperfusion [218, 219], and the use of
glucosamine to bypass GFAT for UDP-GlcNAc production
appears to serve anti-inﬂammatory roles [220, 221]. How-
ever, protective roles of O-GlcNAcylation may be context
dependent. Indeed, hyperglycemia-induced O-GlcNAcyla-
tionofeNOS,dependentontheSer1177residue,occurscon-
comitant with decreased Ser1177 phosphorylation and
reduced NO production [88, 222]. Endothelial O-GlcNA-
cylation is increased in carotid plaques of type II diabetic
patients, and inhibition of the hexosamine pathway is suﬃ-
cient to reverse O-GlcNAcylation-mediated eNOS inhibition
in human coronary endothelial cells in hyperglycemic con-
ditions [223]. O-GlcNAcylation stimulates activation of the
p38, ERK, and JNK pathways in response to hyperglycemia
and contributes to the reduced activation of the insulin
receptor and IR substrate, phosphoinositol-3-kinase, and
Akt [214, 223]. Additionally, hyperglycemia enhances O-
GlcNAcylation of the Sp1 transcription factor regulating
expression of the proﬁbrotic growth factor TGFβ in arterial
endothelial cells [224] and smooth muscle cells [225].International Journal of Vascular Medicine 9
However, no deﬁnitive data exists linking O-GlcNAcylation
to enhanced atherosclerotic plaque formation in diabetic
mice or human patients.
Despite the discovery and characterization of O-GlcNA-
cylation in 1986 [226] and OGT in 1990 [216], no ma-
ture therapeutics have been developed targeting hexosam-
ine stress. Although the glutamine analogs 6-diazo-5-oxo-
L-norleucine and azaserine (O-diazoacetyl-L-serine) are fre-
quently used to study the hexosamine pathway by inhibiting
GFAT activity, the role of GFAT in glycosylation, and
the ubiquitous nature of O-GlcNAcylation make GFAT an
unattractive therapeutic target. However, as the regulation
and contexts of O-GlcNAcylation are further characterized,
newinsightsmayprovethispathwayfeasibleforintervention
of hyperglycemic distress. In contrast, several comprehensive
reviews highlight the escalating, decades-long success story
of aldose reductase inhibitors (ARIs) [227–229]. Although
the majority of ARIs to date have been less eﬀective in hu-
man patients than in experimental models or have exhib-
ited unforeseen but mild/reversible side eﬀects, the ARIs
have consistently demonstrated improvements in peripheral
measures including nerve conduction velocity and sensation,
albuminurea, and peripheral blood ﬂow. Consequently,
pharmaceuticalcompanieshavedevelopedincreasinglymore
potent ARIs. Currently, ranirestat is undergoing phase III
trials in Europe and the United States, and epalrestat has
been used clinically in Japan for several years. While the bulk
of these trials and other experimental data support a proin-
ﬂammatory role for aldose reductase [209], no clinical trials
to date have tested the eﬀectiveness of ARIs in treating
macrovascular complications of diabetes.
3.4. Protein Kinase C (PKC). The PKC family of serine/
threonine kinases regulates a plethora of cellular functions.
MammaliancellsexpressmultiplePKCisoformsdividedinto
subfamilies termed classical PKCs (PKCα,P K C βI, PKCβII,
PKCγ), novel PKCs (PKCδ,P K C ε,P K C η,P K C θ,P K C μ),
and atypical PKCs (PKCζ,P K C λ/ι)[ 230, 231]. Activation
mechanismsdiﬀerbetweensubclasseswithbothclassicaland
novel PKC isoforms showing activation by diacylglycerol,
phosphatidylserine, and phorbol esters (e.g., phorbol-12-
myristate-13-acetate (PMA)), whereas only classical PKCs
are sensitive to calcium due to the presence of a calcium
bindingdomainintheN-terminus[230,231].AtypicalPKCs
are insensitive to calcium and diacylglycerol and are acti-
vated instead by the phosphoinositide 3-kinase (PI-3K)/
phosphoinositide-dependent kinase (PDK1) pathway [230,
231]. Evidence for PKC activation in hyperglycemia has im-
plicated two major pathways leading to PKC activity. First,
high-glucose-induced mitochondrial superoxide production
leads to poly(ADP-ribose) polymerase (PARP) activation,
and subsequent modiﬁcation and inactivation of GAPDH by
ADP-ribose polymers (Figure 3(a)) [72, 232]. GAPDH in-
activation results in accumulation of the upstream glycolysis
intermediate glyceraldehyde-3 phosphate which can be con-
verted to diacylglycerol promoting the activation of classical
and novel PKCs. Second, ligation of the RAGE receptor
by AGEs also stimulates PKC activation albeit through
uncertain mechanisms (Figure 3(b)) [233].
Signaling through PKC regulates multiple cellular pro-
cesses involved in endothelial cell dysfunction and activa-
tion. PKC phosphorylates eNOS on an inhibitory site
(Thr495) blunting eNOS activity [234, 235]a n dr e d u c e s
eNOS phosphorylation on the activating Ser1177 site [236,
237]. TNFα reduces eNOS protein stability through PKCζ
suggesting that PKC inﬂuences NO production through a
variety of mechanisms [238]. Interestingly, a study of the
porcine aorta demonstrated that PKCζ showed enhanced
activity in regions of disturbed ﬂow prone to atherosclerotic
plaque development [239]. Conversely, PKCα shows both
positive and negative eﬀects on eNOS activity and NO pro-
duction depending upon environmental context [240, 241].
In addition to modulating eNOS activity, PKC induces en-
dothelial monolayer permeability directly via phosphor-
ylation of junctional proteins (e.g., occludin) [242, 243]a n d
indirectly through enhanced expression of the permeability-
inducing factors VEGF [244], endothelin-1 [245], and thro-
mbin [246]. Multiple PKC isoforms can feed directly into
the NF-κB activation pathway regulating downstream proin-
ﬂammatory gene expression [247, 248]. Classic PKC iso-
forms PKCα and PKCβ mediate NF-κB activation and ex-
pression of ICAM-1/VCAM-1 in response to 12/15-lipox-
ygenase and apolipoprotein CIII [249, 250]. In contrast,
thrombin-induced NF-κB activation requires the novel iso-
form PKCδ [251, 252]. The atypical isoform PKCζ mediates
TNFα-induced NF-κB activation and ICAM expression
[253]. Taken together, these data suggest that PKC isoforms
play stimulus- and context-dependent roles in modulating
endothelial dysfunction and activation.
A mounting body of evidence implicates PKC signaling
in multiple modalities of hyperglycemia-induced endothelial
cell dysfunction and activation. Hyperglycemia stimulates a
PKC-dependent reduction in eNOS expression and NO pro-
duction in retinal and aortic endothelial cells [254, 255]. In
addition, the PKC activator PMA promotes NADPH oxi-
dase-dependent ROS production, and inhibiting PKC lim-
ited high-glucose-induced ROS in endothelial cells suggest-
ing that PKC may reduce NO levels by inducing ROS-de-
pendent scavenging [256]. The general PKC inhibitor stau-
rosporine and the classical PKC inhibitor Go6976 reduce
hyperglycemia-associated endothelial monolayer permeabil-
ity suggesting that hyperglycemia-induced PKC signaling
promotes endothelial permeability [257, 258]. However, the
eﬀect of PKC signaling on endothelial permeability depends
upon the isoform involved, as PKCδ signaling reduces
endothelial permeability in coronary artery endothelial cells
and is downregulated in the coronary artery of diabetic rats
[259]. Both staurosporine and calphostin, an inhibitor of
classic and novel PKC isoforms, block hyperglycemia-in-
duced NF-κBa c t i v a t i o n[ 92, 260], and a speciﬁc PKCβ in-
hibitor (ruboxistaurin) prevents AGEs-induced ICAM-1 ex-
pression and leukocyte adhesion in HUVECs [261]. Simi-
larly, the PKCβ inhibitor LY379196 prevents hyperglycemia-
induced NF-κBa c t i v a t i o n[ 262], VCAM-1 expression [262],
and apoptosis [263], suggesting PKCβ may be an attractive10 International Journal of Vascular Medicine
target to limit diabetes-associated endothelial activation in
vivo.
Like AGE/RAGE and ROS, PKC appears to regu-
late endothelial dysfunction/activation and atherosclerotic
plaque formation in animal models. PKCα and PKCβII show
enhanced expression and activation in the diabetic macro-
vasculature [264–267], and the general PKC inhibitor bis-
indolylmaleimide-I blunts hyperglycemia-induced leuko-
cyte binding to mesenteric postcapillary venules in vivo
[268]. PKCβ/ApoE double knockout mice develop smaller
atherosclerotic plaques than mice deﬁcient in ApoE alone
[269], and the PKCβ inhibitor ruboxistaurin reduces retinal
and renal complications in diabetic rats while enhancing
ACh-induced aortic vasodilation [270, 271]. In line with
these studies, transient hyperglycemia blunts endothelial-
dependentvasodilationinotherwisehealthyhumansubjects,
and PKCβ inhibition with ruboxistaurin restores normal
endothelial function in these patients [272]. Furthermore,
ruboxistaurin enhanced brachial artery ﬂow-mediated dila-
tion in type 2 diabetics [273] suggesting that this inhibitor
may reduce macrovascular endothelial dysfunction.
4. Conclusions
Multiple pathways drive hyperglycemia-induced endothelial
cell dysfunction and activation including enhanced glycol-
ysis (ROS), the buildup of glycolytic intermediates (polyol
pathway, hexosamine pathway, PKC activation, and AGE
formation), and AGE-modiﬁcation of proteins (ROS, PKC).
Given the interdependent nature of these pathways, it is
not surprising that inhibitors targeting one of these path-
ways profoundly aﬀect hyperglycemia-induced alterations
in endothelial cell function. But which pathways are more
attractive targets for clinical intervention? Trials limiting
polyol pathway ﬂux, AGE production, and RAGE signaling
have shown a signiﬁcant improvement in endothelial cell
function; however these are not being actively pursued to
treat CVD. The PKCβ inhibitor ruboxistaurin shows great
promise to reduce microvascular complications of diabetes
and early results suggest an improvement in endothelial cell
function in CVD patients. However, no trials to date have
examined the eﬀects of ruboxistaurin on diabetes-associated
atherosclerotic burden directly. Prevention of early ROS
productionusingmitochondrialcomplexIIinhibitorsblocks
downstream AGE production and protects endothelial cells
from transitioning to the dysfunctional or activated pheno-
types[119].However,clinicaltrialstotargettheseearlyROS-
dependent pathways have shown less promising results than
those targeting AGE formation or PKC signaling. Consider-
ing the clinical trial data concerning hyperglycemia itself, the
major issue with these studies may simply involve timing of
intervention. Clinical trials for antioxidants typically utilize
patients already at a high risk for CVD, and interventions
for hyperglycemia in these patients showed a similar lack
of beneﬁcial eﬀect. The use of antioxidants early following
the diagnosis of diabetes, especially coupled with intensive
glycemic control, may provide additional beneﬁt later in
life. Consistent with this idea, intensive treatment to lower
hyperglycemia in the DCCT and UKPDS trials demonstrate
the most striking beneﬁt in long-term follow-up studies
10 years after cessation of diﬀerential treatment; no long-
term follow-up studies have been performed for antioxidant
therapies. Therefore, more research is needed in this area if
we are to translate the volumes of cell and molecular biology,
animal research, and clinical trials into eﬀective therapeutic
strategies.
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